CRISPR base editing for tailored tumour detection - 16/07/2026

Targeted genetic manipulation of signal transduction pathways in CAR T cells enhances anti-tumour potency

Chimeric antigen receptor (CAR) T cell therapy has emerged as a highly promising treatment modality but has so far been used almost exclusively for advanced haematologic malignancies. Researchers at the iFIT cluster of excellence in Tübingen have now used CRISPR base-editing technology to introduce precise point mutations into key signalling pathways of CAR T cells, significantly enhancing their long-term persistence and anti-tumour potency.

Researchers at the German Cancer Research Center (DKFZ) have identified a previously unknown key mechanism by which cancer cells suppress the immune system and thus evade the effects of immunotherapies. At the same time, the new study in mouse models and human tumor samples points to a promising way to prevent resistance to immunotherapy.

Researchers at Heidelberg Faculty of Medicine at Heidelberg University, in collaboration with partners from 29 German study centers, have found evidence of a potential biomarker for personalized therapy of acute myeloid leukemia (AML) in a Phase II study. Analyses showed that certain patients could benefit from additional treatment with the drug Motixafortide in addition to standard chemotherapy.

How can effective treatments for neuropsychiatric disorders be developed without having to accept unwanted side effects? Researchers at the NMI have made an important contribution to this field. In their recent paper, “NMDA receptor subtype differential affinity as a key enabler for precision neuropsychiatry,” they demonstrate how specifically targeting subunits of the NMDA receptor opens up new avenues for safer medications.

Which cellular processes ensure that immune responses are controlled precisely? A new study by the Institute of Cell Biology and Immunology Thurgau (BITG) and the University of Konstanz decodes a decisive signalling pathway.

Research jointly led by scientists at the Heidelberg site of the German Center for Lung Research and investigators in Boston at Massachusetts General Hospital and Harvard Medical School identifies a new immunotherapy-based approach for lung fibrosis: reactivating natural killer cell (NK cells) to eliminate senescent fibroblasts, reverse scarring and restore the lung’s ability to heal.

Chronic infections cause long-term changes in key immune cells. T helper cells suppress their immune function to ensure their survival. New targets for vaccines and cancer immunotherapies.

A team of researchers from the Department of Integrative Evolutionary Biology at the Max Planck Institute for Biology Tübingen has discovered that vitamin B12 plays a key role in transmitting behavioural memories across generations. The study shows for the first time how a nutrient from the diet can, without altering the genome, influence behaviour over multiple generations.

In ovarian cancer, immunotherapies using checkpoint inhibitors have so far been effective in only a small number of patients. Researchers at the HI-TRON Mainz* have now discovered that lipid metabolism processes in the tumor microenvironment play a decisive role in how well such therapies work. The findings open up new avenues for using immunotherapies in a more targeted manner, increasing their effectiveness, and overcoming resistance.

Protein activity can be precisely regulated via subtle changes in temperature using heat-sensitive switches. Underlying this capability is a novel modular design strategy developed by researchers at the Institute of Pharmacy and Molecular Biotechnology of Heidelberg University. The strategy allows the integration of sensory domains in various proteins regardless of function or spatial structure.

Artificial intelligence allows tracing the evolution of genetic control elements in the developing mammalian cerebellum. An international research team led by biologists from Heidelberg University as well as the Vlaams Instituut voor Biotechnologie and KU Leuven has now developed advanced AI models that can predict the activity of these elements based solely on their DNA sequence.

When gene mutations are found in the tumor of cancer patients, it is often unclear whether they promote tumor growth or whether a targeted therapy could be effective. A research team led by the Medical Center - University of Freiburg has now compiled a catalog in which over 11,000 gene variants of a central gene family were examined and evaluated for their role in tumor growth.

Researchers from the German Cancer Research Center and the University of Freiburg show how certain painkillers influence the iron metabolism of liver cancer cells and can thus contribute to iron deficiency and anemia in cancer patients.

Why is blood cancer particularly aggressive in some patients? Researchers at Ulm University Hospital have characterised a mutation in the so-called NOTCH1 gene that significantly influences the prognosis of chronic lymphocytic leukaemia (CLL). Remarkably, this mutation is located in the non-coding region of the gene – an area of DNA long considered less relevant for disease mechanisms.

The cellular environment of a tumor can either support or sabotage recovery. The most comprehensive study to date on the tumor microenvironment in low-grade gliomas, conducted by KiTZ, Jena University Hospital, the DKFZ, and Heidelberg University Hospital, shows what a supportive or obstructive “neighborhood” looks like in childhood brain tumors. The study also provides clues as to how tumor communication might be blocked.

A molecular mechanism that contributes to the progression of Alzheimer’s disease has been discovered by a research team of Heidelberg University. The team, using an Alzheimer’s mouse model, demonstrated that a neurotoxic protein-protein complex is responsible for nerve cells in the brain dying off and the resulting cognitive decline. This finding opens up new perspectives for the development of effective treatments.

Designing protein binders from scratch has long been a daunting challenge within the field of computational biology. Researchers have now developed an innovative, training-free pipeline that uses the fundamental principle of shape complementarity to design site-specific protein binders, which are then optimised to fit precisely onto chosen target sites. The researchers tested this on proteins linked to cancer.

Study led by the University of Tübingen: many non-antibiotics weaken the natural protective function of the intestine – with consequences for the colonization with pathogenic bacteria

With its Proof of Concept grants, the European Research Council (ERC) supports scientists in further developing the economic potential of their research results. Two scientists from the German Cancer Research Center (DKFZ) have now received this coveted funding for the second time.

Many people are infected with the Epstein-Barr virus (EBV), and most are unaware of it. However, EBV can sometimes cause cancer, and this pathogen also appears to play an important role in multiple sclerosis and other autoimmune diseases. Researchers have discovered that EBV increases the ability of infected immune cells to migrate. In this way, the pathogen promotes its spread in the body – a discovery that may have therapeutic implications.

Germany's most important award for young scientists honors the development of immunotherapies against malignant brain tumors.

Researchers have developed a promising cellular immunotherapy for the treatment of glioblastomas: They equipped T cells with a receptor that recognizes a protein of the brain tumors that is responsible for the dangerous stem cell properties. The therapeutic T cells directed against this target structure were able to specifically destroy human brain tumors in laboratory experiments and in mice.

University of Tübingen research team shortens the search for attackers that can wipe out multiresistant pathogens – with the aim of treating infections without antibiotics

A research team from the Heidelberg Medical Faculty, the German Cancer Research Center, the Berlin Institute of Health at Charité (BIH) and the Max Delbrück Center has discovered new details about the spread of the incurable bone marrow cancer multiple myeloma in the body: When the cancer cells break out of the bone and multiply outside the bone marrow, a wide variety of tumor cells arise, accompanied by a significantly altered immune response.

Young patients suffering from two aggressive sarcoma types can now participate in the innovative PAMSARC therapy study at the NCT Heidelberg. The study uses molecular biological methods and tests the extent to which a new drug can improve the poor prognosis for these tumours.